TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02537002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A single intravenous dose of matched placebo
Study: NCT03171480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monoket Pill
Description: Intra-vaginal application of Monoket as a cervical ripening agent for pregnant women undergoing induction of labor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The pharmacy has compounded an identical appearing placebo
Study: NCT03586752

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: On-line program
Description: 18 minutes on-line video at home and 30 minutes CPR skill practice at scene in 3 days after watching on-line video
Study: NCT00536159

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medicaid Maternal and Infant Support Services
Description: Enhanced services include home visiting, transportation, psychosocial counseling, multidisciplinary planning, case management, nutritional guidance, and pregnancy and parenting education during pregnancy and infancy. The services are delivered primarily by nurses with occasional visits by social workers or nutritionists. In the county of the study (Kent), women who were assessed were provided intervention services.
Study: NCT02222480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan
Study: NCT00536159

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse-CHW team
Description: A nurse and two CHWs functioned as a team, using visit and clinical guidelines that detailed expected care. Each team provided services for approximately 50-60 families. While occasional visits were made by both providers, most visits were made by either provider alone. Nurses guided the CHW care, led a multidisciplinary team assessment (with social workers, nutritionists, and others), provided crisis intervention and case management, assessed and managed health problems (including screening for depression and mental health care), and had periodic office visits with prenatal providers. CHWs provided relationship-based support by attempting weekly prenatal contact that alternated phone and face-to-face visits and used peer role modeling and personal empowerment approaches.
Study: NCT02222480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02119143

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamines and minerals
Description: given for 24 weeks, after 4 week wash out of all supplements and dietetic products

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: given for 24 weeks, after 4 weeks wash out of all supplements and dietetic products
Study: NCT02163590

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2Hz mobilisation
Description: This intervention will be applied for 3 sets of 1 minute, with 1 minute rest period in between each set.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0,5Hz mobilisation
Description: This intervention will be applied for 3 sets of 1 minute, with 1 minute rest period in between each set.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intervention that mimics the experimental procedures
Study: NCT03265054

Intervention type: BIOLOGICAL
Intervention: Analysis of plasma samples
Description: Measuring microparticles (MPs) in Human Plasma Samples

Intervention type: BIOLOGICAL
Intervention: Analysis of plasma samples
Description: Measuring microparticles (MPs) in Human Plasma Samples
Study: NCT02355067

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Media Intervention
Description: These women will participate in the intervention through the online Facebook group.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional In-Person Intervention
Description: These women will participate in the intervention through a traditional weekly meeting of a group in-person.
Study: NCT03143114

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Myomectomy
Description: Laparotomy then incision in the uterine wall to remove the myoma followed by closure of the uterine incision
Study: NCT01257464

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: 100mg po one dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill po one dose
Study: NCT02564302

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MUSE Headband
Description: MUSE Headband will help patients with mindfulness.
Study: NCT00621608

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy
Description: Hyperbaric Oxygen Therapy (HBOT) will be provided 5 days per week for 6 weeks for a total of 30 treatments on average. Subjects will be placed into the hyperbaric chamber for approximately 90 minutes of HBOT at 2.4 ATA (partial pressure of oxygen = 1,800 mmHg) when inside the chamber. Subjects will receive dressing changes as required per standard of care.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Placebo Hyperbaric Oxygen Chamber
Description: Patients will receive HBOT placebo 5 days per week for 6 weeks for a total of 30 treatments. Each patient will be placed into the hyperbaric chamber and will receive 90 minutes of room air while inside the chamber and the initial flow of air into the chamber will produce a small increase in pressure (0.3 ATA partial pressure of oxygen = 210 mmHg) which will then be released over a period of 10 minutes. Subjects will receive dressings changes as required per standard of care.
Study: NCT03633305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypnotics
Description: Medication used 1 to 7 nights/week for 6 to 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypnotics
Description: Medication used 1 to 7 nights/week for 6 to 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypnotics
Description: Medication used 1 to 7 nights/week for 6 to 8 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online CBT
Description: Internet self-help program for insomnia with 6 cores.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online CBT
Description: Internet self-help program for insomnia with 6 cores.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-to-face CBT
Description: Face-to-face therapy with 3 to 4 individual sessions in a period of 6 to 8 weeks.
Study: NCT02463201

Intervention type: BEHAVIORAL
Intervention: Weight loss
Study: NCT02243202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: 300 mg capsule, taken once daily, orally for 26 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: 300 mg capsule, taken once daily, orally for 26 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine
Description: 15 mg capsule, taken once daily, orally for 26 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine
Description: 15 mg capsule, taken once daily, orally for 26 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo to Canagliflozin
Description: Placebo capsules look like canagliflozin but do not contain any active drug, taken once daily, orally for 26 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo to Canagliflozin
Description: Placebo capsules look like canagliflozin but do not contain any active drug, taken once daily, orally for 26 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo to Phentermine
Description: Placebo capsules look like phentermine but do not contain any active drug, taken once daily, orally for 26 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo to Phentermine
Description: Placebo capsules look like phentermine but do not contain any active drug, taken once daily, orally for 26 weeks.
Study: NCT03499522

Intervention type: OTHER
Intervention: Observational group
Description: The dependent variables (pain, quality of life, anxiety and coping strategies) and the outcome measures used to measure these variables will be:~* Numerical scale of pain~* Short Form 36 Health Survey \[SF-36\].~* State-Trait Anxiety Inventory \[STAI\].~* Tampa Scale of Kinesiophofia \[TSK-11SV\].~* Pain catastrophizing scale \[PCS\].~* Coping Strategies Questionnaire \[CSQ\].
Study: NCT01718002

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Educational video
Description: The patient was asked to execute the technique used daily oral hygiene that, with the sequence, movements and technical procedures for its implementation evaluated and recorded an instrument to analyze the steps of oral hygiene. Subsequently, patients watched the video prepared individually in the ward where they were interned. After this step, the patient demonstrated again the procedure for oral hygiene. At this point the researcher also observed the sequence, movements and technical procedures used to analyze the steps of oral hygiene, using the same instrument for such employee initially.
Study: NCT03092375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir (G/P) 300mg/120mg
Description: daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir (G/P) 300mg/120mg
Description: daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir (G/P) 300mg/120mg
Description: daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir (G/P) 300mg/120mg
Description: daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin 200Mg Tablet
Description: Weight-based 1000-1200 mg
Study: NCT04288921

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Swab
Description: Swab samples for diagnostic test

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Swab
Description: Swab samples for diagnostic test
Study: NCT04545567

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RocketAP
Description: Artificial pancreas system which is designed to be able to identify when you have eaten and provide insulin for this meal

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: USS Virginia
Description: Artificial pancreas system which responds to glucose fluctuations by modulating insulin delivery but does not specifically detect meal ingestion
Study: NCT02272907

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Injection of saline solution into specimen to test bursting pressure.
Description: A 1 cm gastrotomy will be made with a purse-string suture placed around the defect. A fluid-instillation catheter will be inserted into the specimen via the gastrotomy. The purse-string suture will then be secured around the catheter. The catheter will be fenestrated with a flange to prevent leakage from the gastrotomy site. The catheter will be attached to a Biopac pressure-monitoring device to monitor pressure within the lumen of the specimen. The specimen will then be suspended in a water bath and methylene blue saline solution will be injected into the specimen to a pressure reading of 0. This will be time zero for our experiment. Methylene blue saline solution will then be injected steadily in incremental levels. During this process, the study team will observe for any obvious blue dye leaks at the staple line or drop in pressure on the monitor.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Injection of saline solution into specimen to test bursting pressure.
Description: A 1 cm gastrotomy will be made with a purse-string suture placed around the defect. A fluid-instillation catheter will be inserted into the specimen via the gastrotomy. The purse-string suture will then be secured around the catheter. The catheter will be fenestrated with a flange to prevent leakage from the gastrotomy site. The catheter will be attached to a Biopac pressure-monitoring device to monitor pressure within the lumen of the specimen. The specimen will then be suspended in a water bath and methylene blue saline solution will be injected into the specimen to a pressure reading of 0. This will be time zero for our experiment. Methylene blue saline solution will then be injected steadily in incremental levels. During this process, the study team will observe for any obvious blue dye leaks at the staple line or drop in pressure on the monitor.
Study: NCT02357004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: CR 40 mg daily in addition to normal BP medications

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Description: 12.5 mg daily in addition to normal BP medications
Study: NCT03746054

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Optimal medical treatment
Description: Life style modifications, Monitoring of the risk factors and Optimal medical treatment Lipid-lowering treatment, anti-platelet treatment and ACEi or AT2 antagonists treatment for a total duration of 24 months

Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: usual clinical practice
Description: usual clinical practice in each center
Study: NCT02272907

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Injection of saline solution into specimen to test bursting pressure.
Description: A 1 cm gastrotomy will be made with a purse-string suture placed around the defect. A fluid-instillation catheter will be inserted into the specimen via the gastrotomy. The purse-string suture will then be secured around the catheter. The catheter will be fenestrated with a flange to prevent leakage from the gastrotomy site. The catheter will be attached to a Biopac pressure-monitoring device to monitor pressure within the lumen of the specimen. The specimen will then be suspended in a water bath and methylene blue saline solution will be injected into the specimen to a pressure reading of 0. This will be time zero for our experiment. Methylene blue saline solution will then be injected steadily in incremental levels. During this process, the study team will observe for any obvious blue dye leaks at the staple line or drop in pressure on the monitor.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Injection of saline solution into specimen to test bursting pressure.
Description: A 1 cm gastrotomy will be made with a purse-string suture placed around the defect. A fluid-instillation catheter will be inserted into the specimen via the gastrotomy. The purse-string suture will then be secured around the catheter. The catheter will be fenestrated with a flange to prevent leakage from the gastrotomy site. The catheter will be attached to a Biopac pressure-monitoring device to monitor pressure within the lumen of the specimen. The specimen will then be suspended in a water bath and methylene blue saline solution will be injected into the specimen to a pressure reading of 0. This will be time zero for our experiment. Methylene blue saline solution will then be injected steadily in incremental levels. During this process, the study team will observe for any obvious blue dye leaks at the staple line or drop in pressure on the monitor.
Study: NCT03063086

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QVM149 150/50/80 μg o.d.
Description: A
Study: NCT02318043

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inhaled corticosteroids (usually budesonide/fomorterol 160/4.5mcg; fluticasone/salmeterol 250/50mcg)
Description: Patients with uncontrolled and partly controlled asthma, following accomplishment of study 1, were invited to participate in observational study (study 2), which sought to determine usefulness of both BPTs in reflecting improvement of asthmatic symptoms following 3 and 6 months of moderate-dose ICSs treatment (400\~800μg budesonide or equivalent). Patient continued to administer their original ICS during follow-up. During two follow-up visits (3 months apart), AMP-BPT, His-BPT and Hogg's symptom scores were reassessed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inhaled corticosteroids (usually budesonide/fomorterol 160/4.5mcg; fluticasone/salmeterol 250/50mcg)
Description: Patients with uncontrolled and partly controlled asthma, following accomplishment of study 1, were invited to participate in observational study (study 2), which sought to determine usefulness of both BPTs in reflecting improvement of asthmatic symptoms following 3 and 6 months of moderate-dose ICSs treatment (400\~800μg budesonide or equivalent). Patient continued to administer their original ICS during follow-up. During two follow-up visits (3 months apart), AMP-BPT, His-BPT and Hogg's symptom scores were reassessed.
Study: NCT02767583

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exams
Description: Patients the eligibility criteria will be proposed at the first consultation in central obesity, participate in a clinical study to assess the prevalence of subclinical damage peripheral nerves by simple and painless rapid measurement of skin conductance on the palm of the feet with the Sudoscan® device during the consultation and a Thermotest®, as well as monitoring during the various follow-up consultation after any bariatric surgery or not. This monitoring will be done by the same neurophysiological tests.
Study: NCT03063086

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QVM149 150/50/80 μg o.d.
Description: A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QVM149 150/50/80 μg o.d.
Description: A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QVM149 150/50/80 μg o.d.
Description: A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QVM149 150/50/80 μg o.d.
Description: A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QVM149 150/50/80 μg o.d.
Description: A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QVM149 150/50/160 μg o.d.
Description: B

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QVM149 150/50/160 μg o.d.
Description: B

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QVM149 150/50/160 μg o.d.
Description: B

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QVM149 150/50/160 μg o.d.
Description: B

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QVM149 150/50/160 μg o.d.
Description: B

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QVM149 150/50/160 μg o.d.
Description: B

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salmeterol/fluticasone FDC 50/500 μg b.i.d.
Description: C

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salmeterol/fluticasone FDC 50/500 μg b.i.d.
Description: C

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salmeterol/fluticasone FDC 50/500 μg b.i.d.
Description: C

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salmeterol/fluticasone FDC 50/500 μg b.i.d.
Description: C

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salmeterol/fluticasone FDC 50/500 μg b.i.d.
Description: C

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salmeterol/fluticasone FDC 50/500 μg b.i.d.
Description: C
Study: NCT00527033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM178
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM178
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM178
Description: Oral
Study: NCT03013946

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Concomitant coaching
Description: The corner stones of the pro-active coaching are as follows:~* Patient education:~  * Information on nature and severity of treatment emergent AEs~ * information about remedies for TEAEs~ * propagation and explanation of tests and treatment decisions~ * Patient instruction on self-care and preventive measures~* Preemptive AE treatment strategies~* Supervision of reported ADR severity, ADR mitigation strategies according to recommendations of the PREPARE protocol and cancer treatment modification by treating physician in close collaboration with the coach
Study: NCT00527033

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study: NCT03896009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXS-07 (MoSEIC meloxicam and rizatriptan)
Description: AXS-07 taken once upon onset of a qualifying migraine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meloxicam
Description: Meloxicam taken once upon onset of a qualifying migraine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rizatriptan
Description: Rizatriptan taken once upon onset of a qualifying migraine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken once upon onset of a qualifying migraine.
Study: NCT03897062

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suvorexant 20 mg
Description: Placebo controlled double blind suvorexant vs placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo controlled double blind suvorexant vs placebo
Study: NCT02124889

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly Internet surveys
Description: Subjects will receive weekly Internet surveys asking them how their treatment is working, how often they took the medication, and how easy it was to use the medication.
Study: NCT04098406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNM-Au8
Description: CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a nominal concentration of 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose 60 mL HDPE containers.
Study: NCT05269173

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flos gossypii flavonoids tablet
Description: The distribution ratio between the groups was 1:1:1, and the stratification factor was the degree of illness CDR score. In the study, the entry of each subject into the high-dose group, low-dose group or placebo group will be determined by the randomized system.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flos gossypii flavonoids tablet
Description: The distribution ratio between the groups was 1:1:1, and the stratification factor was the degree of illness CDR score. In the study, the entry of each subject into the high-dose group, low-dose group or placebo group will be determined by the randomized system.
Study: NCT04098406

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was liquid with identical color and taste